Aduro BioTech Inc (NASDAQ:ADRO) price target set to $10.00 by HC Wainwright

Analyst Ratings For Aduro BioTech Inc (NASDAQ:ADRO)

Story continues below

Today, HC Wainwright set its price target on Aduro BioTech Inc (NASDAQ:ADRO) to $10.00 per share.

There are 5 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.

The current consensus rating on Aduro BioTech Inc (NASDAQ:ADRO) is Buy with a consensus target price of $15.20 per share, a potential 181.48% upside.

Some recent analyst ratings include

  • 3/5/2018-Cantor Fitzgerald Reiterated Rating of Buy.
  • 3/2/2018-Canaccord Genuity Reiterated Rating of Buy.
  • 10/2/2017-William Blair Reiterated Rating of Outperform.
  • 7/18/2017-Cowen initiated coverage with a Outperform rating.

Recent Insider Trading Activity For Aduro BioTech Inc (NASDAQ:ADRO)
Aduro BioTech Inc (NASDAQ:ADRO) has insider ownership of 5.00% and institutional ownership of 47.42%.

  • On 7/17/2018 Elsas Andrea Van, Insider, sold 10,454 with an average share price of $6.96 per share and the total transaction amounting to $72,759.84.
  • On 6/1/2018 Stephen T Isaacs, Insider, sold 40,000 with an average share price of $8.68 per share and the total transaction amounting to $347,200.00.
  • On 5/17/2018 Blaine Templeman, Insider, sold 2,000 with an average share price of $8.15 per share and the total transaction amounting to $16,300.00.
  • On 5/9/2018 Stephen T Isaacs, CEO, sold 40,000 with an average share price of $8.01 per share and the total transaction amounting to $320,400.00.
  • On 4/2/2018 Stephen T Isaacs, Insider, sold 40,000 with an average share price of $8.91 per share and the total transaction amounting to $356,400.00.
  • On 3/9/2018 Stephen T Isaacs, Insider, sold 72,051 with an average share price of $8.48 per share and the total transaction amounting to $610,992.48.
  • On 2/26/2018 Elsas Andrea Van, Insider, sold 6,874 with an average share price of $6.48 per share and the total transaction amounting to $44,543.52.

About Aduro BioTech Inc (NASDAQ:ADRO)
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.

Recent Trading Activity for Aduro BioTech Inc (NASDAQ:ADRO)
Shares of Aduro BioTech Inc closed the previous trading session at 5,40 −0,45 7,69 % with 5.85 shares trading hands.

An ad to help with our costs